X
Fotivda approved in Scotland for kidney cancer
https://pharmaphorum.com/news/fotivda-scotland-kidney-cancer/
kidney cancer
Ipsen takes on BMS as kidney cancer pill launches in EU
Cabometyx could take market share from Opdivo
US regulator approves new use for Pfizer’s Sutent
FDA granted new kidney cancer indication despite advisers’ split decision
FDA advisers split on new kidney cancer use for Pfizer’s Sutent
Committee could not decide if Sutent can be used after the removal of a cancerous kidney.
EUSA Pharma’s Fotivda approved in EU for kidney cancer
UK pharma gets licence for second cancer drug
BMS shares fall after latest Opdivo disappointment
BMS waiting for overall survival data of Opdivo and Yervoy in kidney cancer
NICE does U-turn, backs Opdivo in kidney cancer
Price cut and new data sways NICE.
Ipsen/Exelixis’ drug approved in EU for kidney cancer
Cabometyx secures new indication in renal cell carcinoma.
